Jazz Pharmaceuticals plc (JAZZ) | Finance information

Compare Jazz Pharmaceuticals plc

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
Jazz Pharmaceuticals plc	16.6	0%	11%	1.8	1.5
Market Avg	59.7	1.27%	30%	-	0.9
Healthcare Avg	64.5	1.29%	15%	7.1	0.8

$188.00

Target Price by Analysts

72.1% upsideJazz Pharmaceuticals plc Target Price Details

$126.07

Current Fair Value

15.4% upside

Undervalued by 15.4% based on the discounted cash flow analysis.

Share Statistics

Market cap	$6.88 Billion
Enterprise Value	$10.97 Billion
Dividend Yield	$0.0 (0.0%)
Earnings per Share	$5.76
Beta	0.71
Outstanding Shares	63,000,000
Avg 30 Day Volume	608,540

Return

Return on Equity	-
Return on Assets	-
Return on Invested Capital	-

Valuation & Multiples

P/E Ratio	16.59
PEG	-11.93
Price to Sales	1.82
Price to Book Ratio	1.85
Enterprise Value to Revenue	2.86
Enterprise Value to EBIT	18.45
Enterprise Value to Net Income	26
Total Debt to Enterprise	0.52
Debt to Equity	1.53

Revenue Sources

No data

ESG Score

No data

About Jazz Pharmaceuticals plc

1,210 employees

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of...